Evidence map›Paper›PMID 38164150›Full record

ReviewTheranostics2024

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

Susan Richter, Charlotte Steenblock, Alessa Fischer, Sandy Lemm, Christian G Ziegler, Nicole Bechmann, Svenja Nölting, Jens Pietzsch, Martin Ullrich

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Dual‑targeted radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Observational
  3. [European journal of nuclear medicine and molecular imaging · 2026
    Observational
  4. Review
  5. Article
  6. Article
  7. Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  8. Article
  9. Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Susan RichterInstitute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Charlotte SteenblockDepartment of Internal Medicine III, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Alessa FischerDepartment of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich, Switzerland.
Sandy LemmDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Christian G ZieglerDepartment of Internal Medicine III, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Nicole BechmannInstitute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Svenja NöltingDepartment of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich, Switzerland.
Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Martin UllrichDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
University of Zurich · CHUniversity Hospital Carl Gustav Carus · DEUniversity Hospital of Zurich · CHHelmholtz-Zentrum Dresden-Rossendorf · DETU Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [

Indexed as

Carcinoma, NeuroendocrineNeuroendocrine Tumors3-IodobenzylguanidineHumansOctreotideQuality of LifeRadioisotopes3-IodobenzylguanidineOctreotideRadioisotopes

Identifiers

PMID38164150
PMCPMC10750207
OpenAlexW4388028151

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.